Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.09.2012 | short review | Ausgabe 3/2012

memo - Magazine of European Medical Oncology 3/2012

ASH update 2011: chronic lymphocytic leukemia and indolent lymphoma

Zeitschrift:
memo - Magazine of European Medical Oncology > Ausgabe 3/2012
Autor:
MD Michael Steurer

Abstract

At the annual meeting of the American Society of Hematology (ASH) 2011, the focus in the field of chronic lymphocytic leukemia (CLL) and indolent lymphomas was again rather the translation of basic research results into early clinical trials than introducing new treatment standards. Although still at an early phase in the process of drug development, the results achievable with the Bruton’s tyrosine kinase inhibitor ibrutinib (formerly PCI-32765) in CLL and mantle cell lymphoma (MCL) are promising. Concerning clinical practice, new or updated results of trials exploring lenalidomide as well as new monoclonal antibodies (obinutuzumab, ofatumumab) in CLL/indolent lymphoma underscore the clinical value of these drugs, but their definite place in the respective treatment algorithm still needs to be defined.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 3/2012

memo - Magazine of European Medical Oncology 3/2012 Zur Ausgabe